Search

Search results

Ascenion’s portfolio company OMEICOS raises EUR 17 million

Following the successful completion of a Phase I trial with its cardioprotective lead candidate OMT-28, OMEICOS has now closed a Series C financing led by new investor Forbion. The existing investors Vesalius Biocapital II S.A. SICAR, Remiges BioPharma Fund, SMS group GmbH, KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH & Co. KG and The Falck Revocable Trust participated as well. The company will use the proceeds of EUR 17 million to finance a placebo controlled, double-blinded, randomized Phase II trial on OMT-28 in patients with persistent atrial fibrillation, the most common cardiac arrhythmia in humans. In parallel, OMEICOS will drive the expansion of its pipeline into novel indications including eye diseases. Developments in the field of ophthalmology will be led by the company’s US subsidiary OMEICOS Ophthalmics in Boston, MA.

Further information
See OMEICOS’ press release